Expression of rheumatoid factor and C-reactive protein during type Ⅱ collagen treatment of osteoarthritis

doi:10.3969/j.issn.2095-4344.2013.11.016

Abstract

Abstract:

BACKGROUND: Type Ⅱ collagen and chondroitin sulfate are the major components of articular cartilage. They cannot only protect the cartilage, but also inhibit pathology of osteoarthritis.
OBJECTIVE: To evaluate the curative effect of type Ⅱ collagen injection and type Ⅱ collagen- chondroitin sulfate composite injection on osteoarthritis by detecting the expression of rheumatoid factor and C-reactive protein.
METHODS: A rat model of knee osteoarthritis was established by using improved Hulth’s method. The treatment was performed via injection into the articular cavity (treatment group A: type Ⅱ collagen injection; treatment group B: type Ⅱ collagen-chondroitin sulfate composite injection; positive control: sodium hyaluronate; model control: physiological saline). After operation, rats in each group were characterized with daily observation, weighing, serum antibody test and histological observation.
RESULTS AND CONCLUSION: After treatment, the content of rheumatoid factor and C-reactive protein in rats’ serum of model group was increased, and inflammation was aggravated; while compared with the model group, the content of rheumatoid factor and C-reactive protein in the other groups, especially in the treatment group B, were lower and the inflammation was eased (P < 0.01). The findings show that both type Ⅱ collagen and sodium hyaluronate can prevent and treat osteoarthritis effectively. The therapeutic effect of type Ⅱ collagen combined with chondroitin sulfate is better.

Key words: tissue construction, basic experiment in tissue construction, Ⅱ collagen, chondroitin sulfate, osteoarthritis, rheumatoid factor, C-reactive protein, sodium hyaluronate, animal models, improved Hulth’s method, inflammation, cartilage lesions, provincial grants-supported paper, tissue construction photographs- containing paper

CLC Number:

R318

Lei Jing, Zhong Cui-hong, Chen Dan-chang, Huang Lei. Expression of rheumatoid factor and C-reactive protein during type Ⅱ collagen treatment of osteoarthritis[J]. Chinese Journal of Tissue Engineering Research, 2013, 17(11): 2007-2012.

Figures/Tables 4

References

[1] Hou DC, Liu YL, Tai DX, et al. Zhongyi Zhenggu.2006；18(07) : 73-74. 侯德才,刘元禄,邰东旭,等.骨性关节炎的病因与机制研究进展[J]. 中医正骨, 2006, 18(07): 73-74.

[2] Xin KH. Zhongguo Shequ Yishi: Yixue Zhuanye.2012;14: 101. 辛克弘.透明质酸钠治疗骨关节炎的疗效分析[J]. 中国社区医师: 医学专业, 2012, 14: 101.

[3] Wang DL, Geng CY, Jiang LP, et al. Zhongguo Zuzhi Gongcheng Yanjiu yu Linchuang Kangfu.2011;15(28): 5145-5148. 王大利,耿成燕,姜丽平,等.关节软骨及骨破坏模型大鼠经盐酸氨基葡萄糖干预的最佳剂量[J]. 中国组织工程研究与临床康复, 2011, 15(28): 5145-5148.

[4] Ma PQ. Shanghai Yiyao.2011;32(7): 344. 马培奇.美国FDA批准布洛芬-法莫替丁复合片剂Duexis治疗类风湿性关节炎和骨关节炎患者[J]. 上海医药, 2011, 32(7): 344.

[5] Zhang L, Wu LH, Li l, et al. Jianyan Yixue yu Linchuang.2012；9(6): 701-703. 张玲,吴丽华,李玲,等.5种指标在类风湿关节炎中的诊断价值[J]. 检验医学与临床, 2012, 9(6): 701-703.

[6] Li M, Wuli JBTE. Zhongguo Zhongyiyao Keji.2012;19(1): 1-2. 黎明,乌力吉巴特尔.类风湿关节炎蒙医证型与RF、ESR、CRP变化的相关性研究[J]. 中国中医药科技, 2012, 19(1): 1-2.

[7] Liang PH, Li SM, Ye CT, et al. Zhongguo Linchuang Kangfu. 2005;42(9): 88-89. 梁佩红,李斯明,叶春婷,等. Ⅱ型胶原预防和治疗骨关节炎的动物实验[J].中国临床康复, 2005, 42(9): 88-89.

[8] He ZX, Jin Y, Zhang TM. Zhongguo Yaoxue Zazhi.2012;47(5): 387-391. 何兆雄,金艳,张天民.硫酸软骨素的结构及其在骨关节炎治疗中的应用[J].中国药学杂志, 2012, 47(5): 387-391.

[9] Nagler AC. Suppression of type II collagen-induced arthritis by intragastric administration of soluble type II collagen. Proc Natl Acad Sci U S A.1986;83(19): 7443-7446.

[10] Vollenhoven RF. Tolerance induction by a poorly arthritogenic collagen II can prevent collagen-induced arthritis. Cell Immunol. 1988;115(1): 146-155.

[11] Ding CH, Li Q, Xiong ZY. Oral administration of type II collagen suppresses pro-inflammatory mediator production by synoviocytes in rats with adjuvant arthritis. Clin Exp Immunol. 2003;132(3): 416-423.

[12] Trentham DE. Effects of oral administration of type II collagen on rheumatoid arthritis. Science.1993;261(5129): 1727-1730.

[13] Trentham DE. New focus on treatment for rheumatoid arthritis. Curr Opin Rheumatol.1993;5(2): 178-183.

[14] Park KS, Park MJ, Cho ML, et al. Type II collagen oral tolerance; mechanism and role in collagen-induced arthritis and rheumatoid arthritis. Mod Rheumatol. 2009;19(6): 581-589.

[15] Stancikova M, Stancik R, Gubzova Z, et al. Collagen in the treatment of rheumatic diseases--oral tolerance. Bratisl Lek Listy.1999;100(10): 567-571.

[16] Yu Y, Zhang XN, Cheng XD, et al. Xiandai Shengwu Yixue Jinzhan.2009 ;16 : 114-116. 余妍,张小宁,程小东,等.抗RA33抗体、RF、CRP、ANA与ENA联合检测在类风湿性关节炎患者诊断、治疗及预后中的作用[J]. 现代生物医学进展, 2009, 16: 114-116.

[17] Ren DJ, Pu XZ, Yu W. Zhongwai Jiankang Wenzhai.2010; 7(27): 121-123. 任冬娟,朴学哲,于威.抗CCP抗体、RF、CRP及ANA在类风湿性关节炎诊断中的评价[J]. 中外健康文摘, 2010, 7(27):121-123.

[18] Legendre F, Bauge C, Roche R, et al. Chondroitin sulfate modulation of matrix and inflammatory gene expression in IL-1 beta-stimulated chondrocytes-study in hypoxic alginate bead cultures. Osteoarthritis Cartilage.2008;16(1): 105-114.

[19] Cao XJ. Shanxi Yixue Zazhi.2011;40(10): 1433-1434. 曹西军. 膝眼注射骨肽和硫酸软骨素治疗膝关节痛90例[J]. 陕西医学杂志, 2011, 40(10): 1433-1434.

[20] Chen L, Ling PX, Zhang TM. Zhongguo Shenghua Yaowu Zazhi.2008;29(2): 137-139. 陈磊,凌沛学,张天民.硫酸软骨素在骨关节炎防治中的作用[J]. 中国生化药物杂志, 2008, 29(2): 137-139.